pSivida drug target gets FDA priority review

Tue, 08/31/2010 - 2:36pm
Mass High Tech: The Journal of New England Technology

The U.S. Food and Drug Administration has granted priority review status for the New Drug Application of Iluvien, the lead product of Watertown-based biotechnology company pSivida Corp. The drug candidate, which is intended to treat diabetic macular edema (DME), is licensed to Alpharetta, Ga.-based Alimera Sciences Inc.

If approved for priority review, pSivida and Alimera could have news of Iluvien’s status by fourth quarter this year, according to a news release from pSivida.

Approval of the drug could bring in a $25 million milestone payment to pSivida from Alimera, as well as 20 percent of Alimera’s net profits on sales of the drug. In April, pSivida took in a $15 million payment to cover the licensing of Iluvien.

PSivida (Nasdaq: PSVD) develops miniaturized, injectable drug delivery systems for eye patients. Its Iluvien is an insert containing the corticosteroid, fluocinolone acetonide, that goes into the eye of a patient with diabetic macular edema, a disease that causes progressive loss of sight. The company was launched in Australia, and reincorporated as a U.S. company based in Watertown in April of 2008.




Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.